This is a routine annual meeting presentation filing with no new material information. Monitor the Q1 FY2027 earnings release expected September 9, 2026 for the next catalyst. The backlog decline from $214.6M to $165.9M warrants attention in future quarters to assess whether project delivery momentum is sustainable.
Price Chart
Executive Summary
Kewaunee Scientific filed an 8-K furnishing an investor presentation and script for its 2026 Annual Shareholder Meeting. The presentation highlights record FY2026 revenue of $282.0M (up 17.3% YoY), EBITDA of $22.4M, and a strengthened balance sheet with debt-to-equity improving to 0.61-to-1.0. The filing is a routine Regulation FD disclosure of materials already presented at the annual meeting, with no new material financial information or guidance beyond what was previously reported in the 10-K.
Key Facts
- FY2026 revenue reached $282.0M, extending multi-year growth trajectory.
- FY2026 EBITDA was $22.4M, reflecting continued operational improvement.
- Long-term debt reduced by approximately $20M, with debt-to-equity improving to 0.61-to-1.0.
- Consolidated order backlog was $165.9M at April 30, 2026, down from $214.6M in the prior year.
- Lab Products Group (domestic) sales were $214.9M, up 19.8% YoY, including a full year of NuAire results.
- International segment sales were $67.1M, up 9.9% YoY.
- Pre-tax earnings were $13.7M and net earnings were $9.6M.
- The company is advancing SOX 404(b) readiness and building a scalable corporate platform.
Financial Impact
FY2026 revenue $282.0M, EBITDA $22.4M, net earnings $9.6M, debt reduced ~$20M
Risk Factors
- Backlog declined 22.7% YoY to $165.9M, primarily due to completion of large international projects.
- Geopolitical and economic uncertainty could impact project delivery timelines.
- Softer life-sciences market conditions may pressure Lab Products Group margins.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000055529-26-000025 |
| Document: 0000055529-26-000025-index.html | 0000055529-26-000025 |
| Document: 0000055529-26-000025.txt | 0000055529-26-000025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 26, 2026 8w ago | 8-K | $37.88 $34.67 | ▼ −8.47% | ▼ −9.68% | $32.46 (−14.31%) |
Jul 7, 2026 15w ago | DEFA14A | $36.45 $37.37 | ▲ +2.52% | ▲ +1.19% | $32.46 (−10.95%) |
Jun 10, 2026 19w ago | 8-K | $35.76 $35.70 | ▼ −0.17% | ▼ −2.06% | $32.46 (−9.23%) |
Mar 11, 2026 32w ago | 8-K | $35.62 $34.93 | ▼ −1.94% | ▼ −3.91% | $32.46 (−8.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers